Skip to main content

Table 4 Intensity of digestive symptoms (scores) in 40 healthy volunteers assigned to a 7-d consumption of short-chain fructo-oligosaccharides (scFOS) at a dose from 2.5 to 10 g/d or a placebo

From: The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans

scFOS dose (g/d) Excess flatus Bloating Borborygmi Abdominal pain
  d1-d8* d8-d15* P** d1-d8* d8-d15* P** d1-d8* d8-d15* P** d1-d8* d8-d15* P**
0 (placebo) 4.12 ± 1.35 4.12 ± 1.45 *** 3.87 ± 1.80 2.62 ± 0.92 *** 3.25 ± 1.80 2.75 ± 1.47 *** 1.50 ± 1.00 0.50 ± 0.26 ***
2.5 1.75 ± 0.45 3.62 ± 1.28 NS 1.50 ± 0.42 3.12 ± 1.28 0.03 1.37 ± 0.49 300 ± 1.36 NS 1.12 ± 0.61 1.12 ± 0.61 NS
5.0 3.00 ± 1.08 5.25 ± 1.71 NS 1.75 ± 0.97 3.37 ± 1.76 0.03 1.75 ± 0.92 2.87 ± 1.42 NS 0.87 ± 0.51 0.87 ± 0.51 NS
7.5 3.50 ± 0.86 3.50 ± 0.68 NS 1.75 ± 1.03 1.50 ± 0.62 NS 1.75 ± 0.64 0.62 ± 0.32 NS 2.12 ± 0.87 2.12 ± 0.87 NS
10 3.37 ± 1.16 4.75 ± 1.03 NS 2.25 ± 1.06 2.62 ± 1.16 NS 1.50 ± 0.75 1.62 ± 0.86 NS 2.12 ± 0.81 2.12 ± 0.81 NS
  1. *days 1–8 was a run-in period during which no treatment occurred, but subjects excluded from their diet fermented dairy products containing viable bifidobacteria and limited consumption of food products containing high level of non-digestible oligosaccharides.
  2. ** Statistical analyses were performed versus placebo, on the difference d15-d8, using Fisher's Test
  3. *** As the difference days 15-8 with placebo was the reference, p-values are not reported. Symptom intensity was noted every day using a 4-grade scale 0: no symptom; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms. Cumulative daily scores were calculated for each period [d1, d8 a.m.], [d8 p.m., d15] and are reported in the present table as m ± sem. Severity of symptoms and cumulative daily scores can be related via the following scale: 0: no symptom; 1–7: mild symptoms; 8–14: moderate symptoms; 15–21: severe symptoms.